Enter Your Search:
Results 1-2 (2)
Go to page number:
Select a Filter Below
Allergy & Rhinology (1)
Indian Journal of Otolaryngology and Head & Neck Surgery (1)
Erkul, Evren (2)
Babayigit, Mustafa (1)
Cakmak, Adem (1)
Cekin, Engin (1)
Cincik, Hakan (1)
Gungor, Atila (1)
Ipcioglu, Osman (1)
Kuduban, Ozan (1)
Pinar, Dogan (1)
Year of Publication
Evaluation of MMP-9 and TIMP-1 Levels of the Patients with Nasal Polyposis After Corticosteroid Therapies
Indian Journal of Otolaryngology and Head & Neck Surgery
The aim of this study is to evaluate the effects of intrapolyp, systemic and local corticosteroid treatment modalities on MMP-9 and TIMP-1 level in polyp tissues. This study included 71 patients and five groups. Group A treated with oral methylprednisolone, Group B, treated with topical steroid spray, Group C treated with intralesional triamcinolone acetonide, Group D patients with nasal polyposis who has not given any medication, Group E had surgery for concha bullosa without nasal polyp disease. Samples from group A were collected endoscopically 1 day after treatment was stopped. Group B samples were collected at the end of the first month. Video guided sample collection from Group C was also performed on the 7th day after treatment. MMP-9 and TIMP-1 levels were measured by Enzyme-linked immunosorbent assay method. When we compared the MMP-9 levels of all groups, there were no significant differences. There was significant difference of TIMP-1 level between Groups C and E (pC–E = 0.0019), however there was no difference among the level of the other groups. When MMP-9/TIMP1 rates of all groups were compared, there were significant difference between Group A and D (pA–D = 0.005) and between Group A and E, also between Group C and E. Our study is the first study to evaluate the effects of different corticosteroid treatment modalities on MMP-9 and TIMP-1 in nasal polyps and concluded that corticosteroid did not do a significant impact on this pathway.
Nasal polyposis; Matrix metalloproteinase inhibitor; Matrix metalloproteinase-9; Corticosteroid; Therapy
Postoperative cephazolin usage is sufficient for preventing infection after septoplasty procedure
Allergy & Rhinology
The use of antibiotics in septoplasty is a common practice among most ear, nose, and throat doctors; however, there are few studies proving the efficacy, which is considered as unnecessary by some authors. The aim of this pilot study was to evaluate the effect of two different kinds of antimicrobial agent on efficacy and safety after septoplasty surgery and to show that use of cephazolin, 1.0 g, postoperatively, might be sufficient for preventing infection after septoplasty procedure. Patients were randomly divided into two groups with a simple randomization method. The first group of 80 patients received cephazolin, 1.0 g i.v., once postoperatively and the second group of 80 patients received amoxicillin–clavulanate orally for 7 days postoperatively (1000 mg). An early and late postoperative questionnaire and nasal endoscopy evaluation was performed and patients were followed up in the outpatient service to investigate the presence of complications. There was no significant difference in postoperative pain between groups A and B, using visual analog scale scores at the 1st postoperative day. There were no differences related to the amount of purulent discharge found at the lower margin of the inferior turbinate through nasal endoscopy performed on the 14th day postoperatively. There were no statistical significances among groups for complications rates and postoperative endoscopic evaluation. Septoplasties are considered potentially contaminated surgeries, and cephazolin, 1.0 g i.v., given once postoperatively is enough to prevent potential complications with its easy and effective use.
Amoxicillin; antibiotics; cephazolin; complication; postoperative; septoplasty
Results 1-2 (2)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
Canada Institute for Scientific and Technical Information
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.